Cryoprecipitate transfusions in the neonatal intensive care unit: a performance improvement study to decrease donor exposure

Tkach, Erin K.; Mackley, Amy; Brooks, Alison; Kessler, Josh; Paul, David A.

doi:10.1111/trf.14555

Cited by 2 publications

(1 citation statement)

References 12 publications

(25 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 115 Moreover, clinical guidelines have recommended against cryoprecipitate for these conditions unless specific factor replacement products are unavailable because of fewer adverse events. 114 , 116 It has been withdrawn from many European countries because of safety concerns such as the transmission of pathogens. Nevertheless, cryoprecipitate is still available for hemostatic therapy in several countries, including the USA and Canada.…”

Section: Contraindicationsmentioning

confidence: 99%

Use of Cryoprecipitate in Newborn Infants

Maheshwari¹,

Tyagi²,

Guaragni³

et al. 2023

Newborn

View full text Add to dashboard Cite

Cryoprecipitate is a transfusion blood product derived from fresh-frozen plasma (FFP), comprised mainly of the insoluble precipitate that gravitates to the bottom of the container when plasma is thawed and refrozen. It is highly enriched in coagulation factors I (fibrinogen), VIII, and XIII; von Willebrand factor (vWF); and fibronectin. In this article, we have reviewed currently available information on the preparation, properties, and clinical importance of cryoprecipitate in treating critically ill neonates. We have searched extensively in the databases PubMed, Embase, and Scopus after short-listing keywords to describe the current relevance of cryoprecipitate.

show abstract

Section: Contraindicationsmentioning

confidence: 99%

Use of Cryoprecipitate in Newborn Infants

Maheshwari¹,

Tyagi²,

Guaragni³

et al. 2023

Newborn

View full text Add to dashboard Cite

show abstract

Clinical guidelines for cryoprecipitate transfusions

Галстян¹,

Гапонова²,

Жибурт³

et al. 2020

Gematologiâ i transfuziologiâ

View full text Add to dashboard Cite

Background. Cryoprecipitate is made from fresh-frozen plasma (FFP) and contains ﬁbrinogen, factor VIII, factor XIII, von Willebrand factor, ﬁbronectin and ﬁbrinogen.Aim. To provide information on the composition and methods of production, storage, transportation and clinical use of cryoprecipitate.General ﬁndings. Cyoprecipitate is manufactured by slowly thawing FFP at 1–6°C. This precipitates out cryoproteins: factor VIII, von Willebrand factor, factor XIII, ﬁbronectin and ﬁbrinogen. After centrifugation, the cryoproteins are resuspended in a reduced volume of plasma. Cryoprecipitate is stored at temperatures not exceeding –25° С for 36 months. Indications for cryoprecipitate transfusion are hemophilia A, von Willebrand disease, factor XIII deﬁciency, congenital aﬁbrinogenemia and hypoﬁbrinogenemia, acquired hypoﬁbrinogenemia. These indications can occur in obstetrics, neonatology, cardiac surgery, neurosurgery, hematology, orthopaedics, and general surgery during liver transplantation and disseminated intravascular coagulation.

show abstract

Cryoprecipitate transfusions in the neonatal intensive care unit: a performance improvement study to decrease donor exposure

Abstract: Limiting cryoprecipitate transfusions to 1 unit per transfusion decreased donor exposure in infants without negatively impacting posttransfusion fibrinogen levels. This is especially evident in term neonates.

Cited by 2 publications

References 12 publications

Use of Cryoprecipitate in Newborn Infants

Use of Cryoprecipitate in Newborn Infants

Clinical guidelines for cryoprecipitate transfusions

Contact Info

Product

Resources

About